Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q4 FY2017 Earnings Presentation
9 slides from Aurobindo Pharma's earnings presentation, May 29, 2017
Slide 1: Q4 FY16-17 Earnings Presentation
Q4 FY16-17 EARNINGS PRESENTATION 29th May 2017
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 3: Q4 & Full Year FY17: Key Highlights
Q4 & Full Year FY17: Key Highlights • US sales cross US$ 1billion in FY17 • Received final approval for 14 ANDAs in Q4FY17 and 61 ANDAs in FY17 from FDA USA • Filed 31 ANDAs with FDA in FY17 includes 8 ANDAs for the quarter • Launched 35 products during the year and 6 products in Q4FY17 • Received a
Slide 4: US Filings Snapshot
US Filings Snapshot Addressable Cumulative ANDA Filings and Approvals Therapy ANDAs Market Size (US$ Bn) Anti Diabetic 13 5.4 ARV 39 8.0 CNS 82 25.7 Controlled Substances 16 2.3 CVS 69 27.4 Gastroenterological 27 5.0 Ophthalmics 10 0.6 Others 129 14.0 Penem 4 0.5 Respiratory 10 0.6 Oncology 2 0.6 SS
Slide 5: Consolidated Financial Highlights
Consolidated Financial Highlights Q4 FY16-17 • Operating Income at INR 3,642 crore • EBIDTA at INR 721 Cr vs INR 866 crore; EBITDA margin at 19.8%. EBITDA impacted by one-time inventory write-off and other exceptional items • PAT after JV share, minority interest and OCI at INR 532.9 crore • Basic &
Slide 6: Consolidated Financial Performance – Q4FY17
Consolidated Financial Performance – Q4FY17 Q4 Q4 % Value INR Cr EBITDA during the quarter impacted by one-time FY17 FY16 Chg inventory write-off & other exceptional items Formulations 2,879.4 2,966.2 (2.9) API 762.8 774.6 (1.5) Formulations % of sales 79.1% 79.3% Operating Income - Breakup Operatin
Slide 7: Consolidated Financial Performance – FY17
Consolidated Financial Performance – FY17 FY17 FY16 % Chg Operating Income - Breakup Value INR Cr Value in INR Cr FY17 FY16 % Chg Formulations 12,045.4 11,064.4 8.9 USA 6,827.2 6,078.6 12.3 API 3,042.1 2,883.6 5.5 EU 3,277.1 3,130.4 4.7 Emerging markets 755.6 646.1 17.0 Formulations % of sales 79.8%
Slide 8: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-15 Mar-16 Dec-16 Mar-17 Closing Rate1 US$ = 62.50 66.255 67.925 64.85 INR Fx Loan restated in 4,312.3 4,956.7 3,593.7 3,121.5 690 748 529 481 INR Rupee Loan 37.3 46.9 61.9 244.8 Sales Tax Deferment 54.9 41.9 0.5 0.0 Gross Debt 4,404.5 5,045.6 3,656
Slide 9: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725000/5401 +91 98486 67906 Email: ir@aurobindo.com Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Register